Decernotinib is taken orally and its dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg.

Human T-Cells were plated plated in T75 tissue culture flasks at a density of 1
*10(6)/ml. Cells were stimulated with 10 mg/ml phytohemagglutinin at 37C for 72 hours. After 72 hours, cells were detached from the flask by scraping, washed, and plated at a density of 1*10(5)/well in a 96-well plate. decernotinib (9.7 nM to 10 uM) was added, and plates were incubated for 30 minutes at 37C, followed by stimulation with human IL-2. Human B cells were thawed, washed, and resuspended in complete medium. Cells were plated onto a 96-well plate at a density of 2*10(5) cells/well. Decernotinib was added, and plates were incubated for 30 minutes at 37C, followed by stimulation with a combination of 10 ng/ml IL-4 and 1 ug/ml CD40.